{"id":"https://genegraph.clinicalgenome.org/r/673a0c61-9aed-488d-98b7-826590ecca45v1.0","type":"EvidenceStrengthAssertion","dc:description":"The *NTF4* locus was first reported in relation to open-angle glaucoma in 2009 (Pasutto et al., PMID: 20463313), following an earlier genome-wide linkage study identifying markers within the relevant genomic region on chromosome 19q13.33 associated with adult onset primary open angle glaucoma (PMID: 10767336). The first study with genotyping of *NTF4* in affected patients reported 7 cases harboring heterozygous missense variants. All of these cases exhibited optic disc atrophy and glaucomatous visual field defects, however, only 6 out of 7 patients exhibited ocular hypertension. As a result, six cases received a diagnosis of primary open angle glaucoma, while one was diagnosed with normal tension glaucoma. Patientsâ€™ ages of diagnoses formed a broad range of ages (36 years to 80 years) and included one case diagnosed as juvenile primary open-angle glaucoma. Subsequent reports of patients harboring heterozygous variants in *NTF4* have increased the variability of phenotypes and ages of diagnosis, with additional cases of both normal tension and high tension primary open angle glaucoma (PMID: 22815630, PMID: 20806036) and at least one case of primary congenital glaucoma with onset before the age of 1 year and additional phenotypes such as photophobia, corneal opacity, and buphthalmos (PMID: 31367175). Some subsequent studies of *NTF4* genotypes in the glaucoma population have reached other conclusions, with some failing to find *NTF4* variants in large cohorts (PMID: 20215012, PMID: 20463313, PMID: 29540704) and/or raising questions about the pathogenicity of some of the previously identified variants (PMID: 20215012). Per criteria outlined by the ClinGen Lumping & Splitting Working Group, the mode of inheritance was found to be consistent across all of the asserted cases, despite the phenotypic heterogeneity of their clinical presentation. These factors provided a rationale for this curation to lump the diverse cases under a single disease entity, referred to as glaucoma 1, open angle, O (MONDO:0013134). \n\nTwelve potentially deleterious variants were scored as part of this curation (eleven missense and one nonsense), which have been collectively reported in twelve probands in five publications (PMID: 20463313, PMID: 22815630, PMID: 20806036, PMID: 31367175, PMID: 20215012). All probands scored in this curation harbored one variant allele within the *NTF4* locus, and genotyping of other potential causative loci in most cases was limited to *MYOC*, *OPTN*, *WDR36*, and/or *CYP1B1*. The mechanism of pathogenicity in some cases may be monoallelic loss of *NTF4* function, as at least one missense variant was found to be severely reduced or absent at the protein level (PMID: 22815630). On the other hand, an unaffected patient harboring a nonsense variant was identified in the control group of one case-control study (PMID: 20215012), and was intentionally included but not scored in this curation. This finding highlights the absence of evidence in the current patient population for loss of function in *NTF4* as a definitive cause of disease. Some of the candidate alleles are quite common in control populations, suggesting that while they may contribute to the glaucoma susceptibility through a multifactorial mechanism, they are likely insufficient to cause glaucoma on their own. Co-segregation of the variant with affected status has not yet been reported in a family with more than two affected members, so this form of evidence did not play a role in the scoring of this gene-disease relationship.\n\nThis gene-disease association is supported by biochemical studies of the NTF4 gene product, a neurotrophic signaling factor known as neurotrophin 4 that acts as a ligand for the TRKB receptor tyrosine kinase. Treatment of rat neurons with NTF4 protein stimulates their survival and prevents apoptosis when cultured *in vitro* (PMID: 8145295) as well as *in vivo* (PMID: 8159743). NTF4 stimulation of retinal ganglion cells in particular can promote their axonal branching under atrophy-inducing conditions (PMID: 8656282) and can rescue these neuronal cells from injury-induced apoptosis (PMID: 8613749). This neuroprotective effect may be relevant to glaucoma in that neuronal cell death (specifically retinal ganglion cell apoptosis) is a recognized mechanism by which intraocular pressure causes eye injury (PMID: 9920498). On the other hand, the survival benefit of NTF4 treatment on retinal ganglion cells may be short term only (PMID: 9667016). While expression profiling across various human tissues indicates that *NTF4* is highly expressed in a variety of tissue types (PMID: 30239781), its expression within the retina is specific to the ganglion cell layer (PMID: 19765683). Mice with homozygous disruption of the *NTF4* ortholog have been primarily characterized as showing learning and long-term memory defects (PMID: 7746324), while their intraocular pressure may not have been evaluated. However, these animals exhibit reduced neuronal cell content in one of their sensory ganglia (PMID: 8757249) and enhanced loss of retinal ganglion cells in particular after an ischemic injury (PMID: 15671298), indicating that the neuroprotective function of NTF4 may be present in mice. Overall, experimental evidence on *NTF4* is consistent with but not highly supportive of a role in open-angle glaucoma.\n\nIn summary, contradictory evidence has been found to dispute the asserted association between *NTF4* and glaucoma 1, open angle, O. The absence of more complete genotyping of the asserted cases to exclude variants in other potential causative loci and the limited availability of experimental evidence at this time to functionally characterize candidate variants have led to a Disputed classification. This classification was approved by the ClinGen Glaucoma and Neuro-Ophthalmology Gene Curation Expert Panel on December 16th, 2022 (SOP Version 9).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/673a0c61-9aed-488d-98b7-826590ecca45","GCISnapshot":"https://genegraph.clinicalgenome.org/r/144eb479-2c08-47cd-a6d2-8e1abef5cf54","calculatedEvidenceStrength":"Limited","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/144eb479-2c08-47cd-a6d2-8e1abef5cf54_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10077","date":"2022-12-22T04:14:00.857Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/144eb479-2c08-47cd-a6d2-8e1abef5cf54_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10077","date":"2022-12-15T17:00:00.000Z","role":"Approver"}],"curationReasonDescription":"The genotyping of the asserted patients has not been sufficient in many cases to exclude variants in other potential causative loci. Functional characterization of candidate missense variants is largely absent. Experimental evidence is consistent with but not directly supportive of the proposed gene-disease relationship.","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/144eb479-2c08-47cd-a6d2-8e1abef5cf54_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5751e1e0-54b7-43a2-95ec-3365e1021116","type":"EvidenceLine","dc:description":"NM_006179.5(NTF4):c.269G>A (p.Arg90His) is a missense variant in exon 2 of 2 that does not have evidence of an impact on the gene product.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5751e1e0-54b7-43a2-95ec-3365e1021116_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19765683","allele":{"id":"https://genegraph.clinicalgenome.org/r/d1dbb0ba-3cf5-44c7-85fc-eb3ef1f54f69","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006179.5(NTF4):c.269G>A (p.Arg90His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA9565682"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/5c38fa4b-78c2-4500-b1ba-49a6473c748d","type":"EvidenceLine","dc:description":"NM_006179.5(NTF4):c.601T>G (p.Cys201Gly) is a missense variant without experimental evidence of an impact on the function of the gene product.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5c38fa4b-78c2-4500-b1ba-49a6473c748d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31367175","allele":{"id":"https://genegraph.clinicalgenome.org/r/32254cc5-5038-412e-8aec-80806b1ff5a7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006179.5(NTF4):c.601T>G (p.Cys201Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA406804782"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/b019029d-6b4e-4b6e-8af6-39d055538b9b","type":"EvidenceLine","dc:description":"NM_006179.5(NTF4):c.625C>G (p.Arg209Gly) is a missense variant in exon 2 of 2 that does not have evidence of an impact on the gene product.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b019029d-6b4e-4b6e-8af6-39d055538b9b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19765683","allele":{"id":"https://genegraph.clinicalgenome.org/r/ff366c7e-91fd-4ac1-9b09-909887e0df9c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006179.5(NTF4):c.625C>G (p.Arg209Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA9565592"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/598b1564-b6a5-4114-843c-798e824271b0","type":"EvidenceLine","dc:description":"NM_006179.5(NTF4):c.86C>A (p.Ser29Ter) is a nonsense variant in exon 2 of 2 that is predicted to truncate approximately 87% of the C-terminus of the protein product. This proband has not been scored because the variant matches the hypothesized mechanism of pathogenicity, but the phenotype is absent. This indicates that if the gene-disease relationship is ultimately confirmed, penetrance is incomplete or quite mild in a subset of patients.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/598b1564-b6a5-4114-843c-798e824271b0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20215012","allele":{"id":"https://genegraph.clinicalgenome.org/r/2ad1e939-65bd-4063-a186-43710eeac28b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006179.5(NTF4):c.86C>A (p.Ser29Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA406807485"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/fdea6e6c-ce04-443a-b24d-0270e6184257","type":"EvidenceLine","dc:description":"NM_006179.5(NTF4):c.20G>A (p.Cys7Tyr) is a missense variant in exon 2 of 2 that does not have evidence of an impact on the gene product.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fdea6e6c-ce04-443a-b24d-0270e6184257_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19765683","allele":{"id":"https://genegraph.clinicalgenome.org/r/2261d531-e866-44f7-870b-7d14af0909ea","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006179.5(NTF4):c.20G>A (p.Cys7Tyr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA406807744"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/d054355d-33fe-49aa-a973-b0d0ac65ed7e","type":"EvidenceLine","dc:description":"NM_006179.5(NTF4):c.617G>A (p.Arg206Gln) is a missense variant in exon 2 of 2 that does not have evidence of an impact on the gene product.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d054355d-33fe-49aa-a973-b0d0ac65ed7e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19765683","allele":{"id":"https://genegraph.clinicalgenome.org/r/ee0a3f0a-9b45-4e0e-977c-0e6fd5d02cf8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006179.5(NTF4):c.617G>A (p.Arg206Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA123709"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/09421c58-4769-410f-ab53-9a20063ae02e","type":"EvidenceLine","dc:description":"NM_006179.5(NTF4):c.263C>T (p.Ala88Val) is a missense variant in exon 2 of 2 that does not have evidence of an impact on the gene product. A follow-up publication has confirmed that the frequency of this variant in another cohort is higher among controls than among affected (PMID: 20215012). The variant has not been scored for this reason, and because it is present in gnomAD v2.1.1 at a frequency of 0.01795 (541/30146) in the South Asian population","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/09421c58-4769-410f-ab53-9a20063ae02e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19765683","allele":{"id":"https://genegraph.clinicalgenome.org/r/35ff4d58-5776-40aa-858c-636f0fec105b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006179.5(NTF4):c.263C>T (p.Ala88Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA123705"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/5db66033-f01d-47a5-a517-87d3684608bd","type":"EvidenceLine","dc:description":"Despite the functional evidence, the NM_006179.5(NTF4):c.616C>T (p.Arg206Trp) variant has not been scored due to its presence in gnomAD v2.1.1 at a frequency of 0.001539 (197/128040) in the European non-Finnish population.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5db66033-f01d-47a5-a517-87d3684608bd_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_006179.5(NTF4):c.616C>T (p.Arg206Trp) is a missense variant in exon 2 of 2 that has limited evidence of an impact on the gene product. Treatment of PC12 cells with the recombinant variant protein leads to decreased TrkB phosphorylation (Figs. 4B and 4C) and a lower percentage of the cells with neurite outgrowth (Figs. 4D and 4E).Some patients from the cohort had a family history of glaucoma, but it is not clear whether this particular patient was one of them.","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/5db66033-f01d-47a5-a517-87d3684608bd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19765683","allele":{"id":"https://genegraph.clinicalgenome.org/r/c1db7861-ce8b-4f06-a890-b8b57ecdd9b1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006179.5(NTF4):c.616C>T (p.Arg206Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA123707"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/09a76371-7aac-4ff3-b882-0ca7b0a64414","type":"EvidenceLine","dc:description":"NM_006179.5(NTF4):c.250G>A (p.Glu84Lys) is a missense variant in exon 2 of 2 that does not have evidence of an impact on the gene product.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/09a76371-7aac-4ff3-b882-0ca7b0a64414_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19765683","allele":{"id":"https://genegraph.clinicalgenome.org/r/55a4972b-5753-45f4-8479-bd91fbd57c78","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006179.5(NTF4):c.250G>A (p.Glu84Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA9565689"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/4216bf1a-7b54-4fc4-ac0c-07d1cc0330d9","type":"EvidenceLine","dc:description":"NM_006179.5(NTF4):c.338T>C (p.Leu113Ser) does not have experimental evidence of an impact on the function of the gene product.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4216bf1a-7b54-4fc4-ac0c-07d1cc0330d9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20806036","allele":{"id":"https://genegraph.clinicalgenome.org/r/0ffcf5b0-4f69-45d5-a4ad-9e1061fd184b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006179.5(NTF4):c.338T>C (p.Leu113Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA406806487"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/076a3102-57c4-4937-8724-48b946a7aa20","type":"EvidenceLine","dc:description":"The variant was up-scored for evidence of a severe deleterious impact on the gene product at the protein level.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/076a3102-57c4-4937-8724-48b946a7aa20_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_006179.5(NTF4):c.545C>T (p.Ala182Val) is a missense variant with experimental evidence of an impact on the function of the gene product. The variant was detectable at the mRNA level (Fig. 2B) but was absent or dramatically reduced at the protein level according to immunofluorescence (Fig. 2A) and immunoblotting (Fig. 2C).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/076a3102-57c4-4937-8724-48b946a7aa20_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22815630","allele":{"id":"https://genegraph.clinicalgenome.org/r/b12ea645-35c7-45b9-8bc0-e3fbbb7933e3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006179.5(NTF4):c.545C>T (p.Ala182Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA9565609"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/de395f26-e5fe-4879-9547-1d28a2e848be","type":"EvidenceLine","dc:description":"The variant has been up-scored for some evidence of an impact on the gene product.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/de395f26-e5fe-4879-9547-1d28a2e848be_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_006179.5(NTF4):c.470G>C (p.Gly157Ala) is a missense variant with experimental evidence of an impact on the function of the gene product. The variant was less soluble in Triton X-100 than the wild-type protein and was found partially in the insoluble fraction (Figure 2C), consistent with a predicted increase in hydrophobicity (Figure 2D). On the other hand, the immunofluorescence staining pattern of the variant matched the wild-type, indicating proper subcellular trafficking (Figure 2A).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/de395f26-e5fe-4879-9547-1d28a2e848be_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22815630","allele":{"id":"https://genegraph.clinicalgenome.org/r/19859dae-b543-4ae7-b6bf-17194e750ac0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_006179.5(NTF4):c.470G>C (p.Gly157Ala)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA406805502"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.25}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":1.45},{"id":"https://genegraph.clinicalgenome.org/r/144eb479-2c08-47cd-a6d2-8e1abef5cf54_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/144eb479-2c08-47cd-a6d2-8e1abef5cf54_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f4b84a4e-c85f-4b88-817a-e84b0964a10a","type":"EvidenceLine","dc:description":"The model has been scored because the evidence matches the biochemical findings by showing that the NTF4 ortholog promotes the number of neurons in certain ganglia and prevents retinal ganglion cell apoptosis during ischemic injury. Down-scoring has been performed because the homozygous state of the variant does not match.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/db8f3e61-6d65-4187-83db-841b081413e0","type":"Finding","dc:description":"This homozygous mutation does not disrupt growth, viability, fertility, brain size, or behavior (during the first 10 months of life). However, it triggers a 50% decrease in the volume of the nodose-petrosal complex (a sensory ganglion that controls taste but not vision) and a reduction in neuronal number compared to wild-type controls (Table 1, Figure 1). Other neurons in the facial nucleus, lumbar cord, or the vestibular, cochlear, or trigeminal ganglia do not appear to be disrupted. DA transmitter (TH+) neurons were only mildly disrupted (Table 2, Figure 2). It is important to note that these phenotypes are observed in homozygous animals, while the human patients have heterozygous NTF4 disruption.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8757249","rdfs:label":"Murine model of NTF4 loss-of-function","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/144eb479-2c08-47cd-a6d2-8e1abef5cf54_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/00ac385b-b751-4719-8729-40a703167467","type":"EvidenceLine","dc:description":"This evidence has been down-scored due to the uncertainty around whether axonal branching is a factor in the etiology of the disease.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e9914361-886f-454d-8374-1bd33a4efb0e","type":"Finding","dc:description":"Optic nerve atrophy is one of the features identified in open-angle glaucoma patients harboring a variant in the NTF4 gene. This evidence is consistent with the hypothesized role of NTF4 in promoting retinal neuron survival.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8656282","rdfs:label":"NTF4 stimulates axonal branch growth by RGCs.","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/89920f3e-bf2e-4dca-ba5e-41c7892575c4","type":"EvidenceLine","dc:description":"This experiment has been scored because of the degree of rescue by NTF4, but down-scored due to the surgical rather than genetic etiology of the defect in the model and the lack of certainty about whether prevention of apoptotic death of retinal ganglion cells is a critical factor in attenuating glaucoma development.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/58a264d1-eda7-4b33-a60e-55963d2e522a","type":"Finding","dc:description":"Retinal ganglion cell death is thought to be a mechanism by which increased intraocular pressure can lead to eye injury in glaucoma (PMID: 9920498).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8613749","rdfs:label":"NTF4 rescues loss of retinal ganglion cells in rat.","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/c314e091-267a-42f6-911d-8d8fbba27c47","type":"EvidenceLine","dc:description":"While this finding agrees with previous biochemical evidence, it questions their relevance to the development of glaucoma.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/80598563-75c6-44bc-b154-3fc57119c883","type":"Finding","dc:description":"This evidence questions the value of NTF4 in promoting retinal neuron survival, and points to the lack of direct evidence establishing that anti-apoptotic signaling plays a protective role in preventing neuron loss in the context of glaucoma.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9667016","rdfs:label":"NTF4 stimulation of RGC survival after injury is temporary.","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/98550d2d-4b2b-4c61-abd2-ee20a55b0948","type":"EvidenceLine","dc:description":"This evidence links NTF4 to the prevention of neuronal apoptosis, although not specifically to the retinal ganglion cells.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5d0c1c45-5dfc-45f9-a2e3-a1cf67cfea28","type":"Finding","dc:description":"While it is not currently clear how the established effect of NTF4 on neuron survival is linked with the proposed ability of certain variants to contribute to glaucoma risk, neuronal cell death (specifically retinal ganglion cell apoptosis) is a recognized mechanism by which intraocular pressure injures the eye (summarized in PMID: 9920498).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8145295","rdfs:label":"NTF4 stimulates neuron survival in culture.","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/72d943d8-a154-40f7-9b03-afe3e372920d","type":"EvidenceLine","dc:description":"This evidence was scored because of its relevance to the hypothesized mechanism of action by which NTF4 is thought to prevent disease, but down-scored due to the limited relevance of the particular neurons rescued.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/33888e45-2bd5-4a79-8e34-17dc3756918c","type":"Finding","dc:description":"This is consistent with the proposed function of NTF4 as a survival factor for motor neurons as well as peripheral sensory sympathetic neurons.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8159743","rdfs:label":"NTF4 prevents injury-induced death of facial motor neurons.","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/1893a0ee-6178-470e-a036-8e7d21871782","type":"EvidenceLine","dc:description":"The expression pattern within the adult retina is quite convincing and specific, and matches the established effect of NTF4 on neuron survival (PMID: 8145295, PMID: 8159743). However, this evidence was conservatively scored as other datasets indicate that NTF4 expression is also high in apparently unrelated (but innervated) tissues such as the prostate and the skin (PMID: 30239781).","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/912c872b-b0ee-4000-836a-c1c8de60f26e","type":"Finding","dc:description":"NTF4 mRNA was found to be normally expressed particularly in the ganglion cell layer of the adult retina, and to a lesser degree within the photoreceptor segments (Figure 5A). This is consistent with a role in nerve growth factor signaling.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19765683","rdfs:label":"NTF4 expression in the ganglion cell layer of adult retina","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1.75}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":2.25}],"evidenceStrength":"Disputed","sequence":5559,"specifiedBy":"GeneValidityCriteria9","strengthScore":3.7,"subject":{"id":"https://genegraph.clinicalgenome.org/r/sl3uJXeVMwo","type":"GeneValidityProposition","disease":"obo:MONDO_0013134","gene":"hgnc:8024","modeOfInheritance":"obo:HP_0000006"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_144eb479-2c08-47cd-a6d2-8e1abef5cf54-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}